Identifying the patient with heart failure to be treated with vericiguat

Area of Science:

• Cardiology
• Pharmacology

Background:

• Heart failure with reduced ejection fraction (HFrEF) involves complex neurohormonal dysregulation.
• The nitric oxide-soluble guanylate cyclase (sGC)-cGMP pathway is impaired in HFrEF, contributing to cardiac, vascular, and renal issues.
• Current HFrEF treatments may be underutilized or sub-optimally dosed, limiting benefits.

Purpose of the Study:

• To evaluate the efficacy of vericiguat, a novel sGC stimulator, in patients with HFrEF.
• To assess the impact of vericiguat on cardiovascular outcomes in HFrEF.
• To determine if vericiguat offers benefits beyond existing therapies by targeting the sGC-cGMP pathway.

Main Methods:

• The VICTORIA trial investigated the addition of vericiguat to standard therapy in HFrEF patients.
• Patients received a once-daily oral dose of vericiguat.
• Outcomes assessed included the composite of cardiovascular death or heart failure hospitalization.

Main Results:

• Adding vericiguat to standard therapy significantly reduced the risk of cardiovascular death or HF hospitalization by 10% (NNT 24).
• Vericiguat demonstrated a favorable safety profile, without interfering with heart rate, renal function, or potassium levels.
• The drug effectively restores the impaired sGC-cGMP pathway, a mechanism not targeted by other disease-modifying HF drugs.

Conclusions:

• Vericiguat is a valuable therapeutic option for improving prognosis in specific HFrEF patient profiles.
• It offers a unique mechanism of action by stimulating the sGC-cGMP pathway.
• Optimizing HFrEF treatment may involve considering factors like blood pressure and renal function, with vericiguat providing an additional benefit without common contraindications.